ArticleCureus2026
Acute Kidney Injury Following Duloxetine (Cymbalta) Therapy in a 43-Year-Old Female: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Duloxetine is a commonly prescribed serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat depression, anxiety disorders, and chronic pain syndromes. Renal adverse effects are considered rare. We present the case of a 43-year-old female who developed acute kidney injury (AKI) eight weeks after initiating duloxetine and escalating the dose from 30 mg to 60 mg daily, necessitating hospitalization. The patient presented with mental lethargy, disorientation, and generalized weakness and was found to have marked azotemia with a significant reduction in estimated glomerular filtration rate. Her condition improved following intravenous hydration and discontinuation of all medications, with gradual normalization of renal function over approximately six weeks. Notably, the patient had no history of dehydration, gastrointestinal losses, or reduced oral intake before presentation. Hemoglobin and hematocrit levels remained normal throughout the course of AKI. The close temporal association with duloxetine initiation and recovery following drug cessation supports a probable causal relationship. This report highlights the importance of vigilance for potential renal adverse effects associated with SNRIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.